foxo4 dri peptide senolytic human trial Molecular modelling of the FOXO4-TP53 interaction to design peptides for the elimination of senescent cancer cells Frontiers | Senolytic Peptide FOXO4-DRI
Frontiers Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes FOXO4 DRI 10mg Ion Peptide FOXO4 DRI Peptide 10 mg FOXO4 DRI 10mg vial Description RCpeptides The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $7.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17




